← Leaderboards
Stanley R Riddell
Fred Hutchinson Cancer Center
$31,084,866
Attributed
$35,800,593
Total exposure
28
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,800,593 · 28
By mechanism
R01$22,619,751 · 5
P01$4,671,720 · 5
P50$3,451,142 · 3
U01$2,318,322 · 2
P51$1,401,286 · 7
RC1$959,446 · 1
Top collaborators
- Michael C Jensen10 shared
- Marie Bleakley5 shared
- Kristin J Lastwika2 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Marie Bleakley$9,428,742
- Damian J. Green$13,222,447
- Stephen J. Tapscott$35,231,470
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteCellsMalignant NeoplasmsTumorImmunityAntigensIn VivoIn VitroEngineeringT Memory CellImmunotherapyCd8b1 GeneAdoptive TransferResponseClinical TrialsSafetyMemoryCell SurfaceNeoplastic CellDesignTranslatingBaseNonhuman PrimateGrant
Grant awards (95)
Engineering Effective T cell Immunity to Multiple Myeloma$850,024
P01 · FY2025 · CA · contact PI
Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy$435,730
R01 · FY2025 · CA · contact PI
Engineering Effective T cell Immunity to Multiple Myeloma$850,024
P01 · FY2024 · CA · contact PI
Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy$413,943
R01 · FY2024 · CA · contact PI
Translating Autoantibodies Into Chimeric Antigen Receptor-T cell Therapy for Small Cell Lung Cancer$591,527
U01 · FY2023 · CA
Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy$435,730
R01 · FY2023 · CA · contact PI
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy$346,635
P50 · FY2023 · CA · contact PI
Translating Autoantibodies Into Chimeric Antigen Receptor-T cell Therapy for Small Cell Lung Cancer$575,240
U01 · FY2022 · CA
Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy$379,343
R01 · FY2022 · CA · contact PI
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy$346,635
P50 · FY2022 · CA · contact PI
Research Program: Cancer Immunology$82,959
P30 · FY2022 · CA · contact PI
Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy$75,386
R01 · FY2022 · CA · contact PI
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy$263,434
P50 · FY2021 · CA · contact PI
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy$83,022
P50 · FY2021 · CA · contact PI
Research Program: Cancer Immunology$77,762
P30 · FY2021 · CA · contact PI
TARGETING ROR1 WITH CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS$458,731
R01 · FY2020 · CA · contact PI
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy$381,302
P50 · FY2020 · CA · contact PI
TARGETING ROR1 WITH CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS$444,969
R01 · FY2019 · CA · contact PI
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy$346,634
P50 · FY2019 · CA · contact PI
Targeted therapy of B cell malignances with CAR-T cells of defined composition$560,424
R01 · FY2018 · CA · contact PI
Naive T cell depletion to prevent graft-versus-host disease$539,649
R01 · FY2018 · HL
TARGETING ROR1 WITH CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS$458,731
R01 · FY2018 · CA · contact PI
Targeted therapy of B cell malignances with CAR-T cells of defined composition$560,424
R01 · FY2017 · CA · contact PI
Naive T cell depletion to prevent graft-versus-host disease$539,649
R01 · FY2017 · HL
TARGETING ROR1 WITH CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS$458,731
R01 · FY2017 · CA · contact PI
Targeted therapy of B cell malignances with CAR-T cells of defined composition$560,424
R01 · FY2016 · CA · contact PI
Naive T cell depletion to prevent graft-versus-host disease$539,649
R01 · FY2016 · HL
TARGETING ROR1 WITH CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS$458,735
R01 · FY2016 · CA · contact PI
Targeted therapy of B cell malignances with CAR-T cells of defined composition$560,424
R01 · FY2015 · CA · contact PI
Naive T cell depletion to prevent graft-versus-host disease$531,554
R01 · FY2015 · HL · contact PI
Naive T cell depletion to prevent graft-versus-host disease$586,112
R01 · FY2014 · HL · contact PI
Targeted therapy of B cell malignances with CAR-T cells of defined composition$579,424
R01 · FY2014 · CA · contact PI
Strategies to improve the adoptive transfer of T cells$448,945
R01 · FY2014 · CA · contact PI
Targeted immunotherapy of breast cancer with central memory T cells$330,935
P50 · FY2014 · CA · contact PI
Targeted therapy of ALL with gene-modified central memory T cells$508,741
R01 · FY2013 · CA · contact PI
CD8+ T Cell Immunity to Cytomegalovirus$471,690
R01 · FY2013 · AI · contact PI
Strategies to improve the adoptive transfer of T cells$412,706
R01 · FY2013 · CA · contact PI
Targeted immunotherapy of breast cancer with central memory T cells$331,064
P50 · FY2013 · CA · contact PI
Targeted therapy of ALL with gene-modified central memory T cells$542,633
R01 · FY2012 · CA · contact PI
CD8+ T Cell Immunity to Cytomegalovirus$501,799
R01 · FY2012 · AI · contact PI
Targeted immunotherapy of breast cancer with central memory T cells$457,354
P50 · FY2012 · CA · contact PI
Strategies to improve the adoptive transfer of T cells$442,047
R01 · FY2012 · CA · contact PI
Targeting Alloreactivity for Leukemia Eradication$561,787
P01 · FY2011 · CA · contact PI
Targeted therapy of ALL with gene-modified central memory T cells$543,264
R01 · FY2011 · CA · contact PI
CD8+ T Cell Immunity to Cytomegalovirus$499,674
R01 · FY2011 · AI · contact PI
Strategies to improve the adoptive transfer of T cells$445,138
R01 · FY2011 · CA · contact PI
Targeted immunotherapy of breast cancer with central memory T cells$337,324
P50 · FY2011 · CA · contact PI
STRATEGIES TO ENHANCE ADOPTIVE TRANSFER OF T CELL CLONES$156,634
P51 · FY2011 · RR · contact PI
Targeted therapy of ALL with gene-modified central memory T cells$560,754
R01 · FY2010 · CA · contact PI
Targeting Alloreactivity for Leukemia Eradication$542,432
P01 · FY2010 · CA · contact PI
CD8+ T Cell Immunity to Cytomegalovirus$492,596
R01 · FY2010 · AI · contact PI
ANALYSIS OF A NOVEL SUBSET OF HUMAN CD8+ MEMORY CELLS WITH STEM CELL QUALITIES$479,723
RC1 · FY2010 · AI · contact PI
Targeted immunotherapy of breast cancer with central memory T cells$226,803
P50 · FY2010 · CA · contact PI
Strategies to improve the adoptive transfer of T cells$224,371
R01 · FY2010 · CA · contact PI
STRATEGIES TO ENHANCE ADOPTIVE TRANSFER OF T CELL CLONES$155,086
P51 · FY2010 · RR · contact PI
EVALUATING THE ENGINEERING OF CYTOMEGALOVIRUS-SPECIFIC CD8+ T CELL CLONES$155,086
P51 · FY2010 · RR · contact PI
Targeting Alloreactivity for Leukemia Eradication$648,309
P01 · FY2009 · CA · contact PI
Targeted therapy of ALL with gene-modified central memory T cells$551,563
R01 · FY2009 · CA · contact PI
CD8+ T Cell Immunity to Cytomegalovirus$502,469
R01 · FY2009 · AI · contact PI
ANALYSIS OF A NOVEL SUBSET OF HUMAN CD8+ MEMORY CELLS WITH STEM CELL QUALITIES$479,723
RC1 · FY2009 · AI · contact PI
Strategies to Enhance Adoptive Transfer T Cell Clones$396,427
R01 · FY2009 · CA · contact PI
STRATEGIES TO ENHANCE ADOPTIVE TRANSFER OF T CELL CLONES$315,186
P51 · FY2009 · RR · contact PI
Targeting Alloreactivity for Leukemia Eradication$621,411
P01 · FY2008 · CA · contact PI
Strategies to Enhance Adoptive Transfer T Cell Clones$386,144
R01 · FY2008 · CA · contact PI
STRATEGIES TO ENHANCE ADOPTIVE TRANSFER OF T CELL CLONES$434,134
P51 · FY2007 · RR · contact PI
CD8+T Cell Immunity to Cytomegalovirus$410,088
R01 · FY2007 · AI · contact PI
Strategies to Enhance Adoptive Transfer T Cell Clones$383,603
R01 · FY2007 · CA · contact PI
CONSENT TO PARTICIPATE AS A DONOR OF PERIPHERAL BLOOD MONONUCLEAR CELLS$13,984
M01 · FY2007 · RR · contact PI
CD8+T Cell Immunity to Cytomegalovirus$422,336
R01 · FY2006 · AI · contact PI
Strategies to Enhance Adoptive Transfer T Cell Clones$384,876
R01 · FY2006 · CA · contact PI
CONSENT TO PARTICIPATE AS A DONOR OF PERIPHERAL BLOOD MONONUCLEAR CELLS$129,325
M01 · FY2006 · RR · contact PI
STRATEGIES TO ENHANCE ADOPTIVE TRANSFER OF T CELL CLONES$94,326
P51 · FY2006 · RR · contact PI
PHASE I STUDY OF ADOPTIVE IMMUNOTHERAPY AFTER STEM CELL TRANSPLANT$1,655
M01 · FY2006 · RR · contact PI
CD8+T Cell Immunity to Cytomegalovirus$432,500
R01 · FY2005 · AI
Strategies to Enhance Adoptive Transfer T Cell Clones$399,222
R01 · FY2005 · CA
Conditional Regulation of T Cell Survival in Immunotherapy$382,055
U01 · FY2005 · HL
CONSENT TO PARTICIPATE AS A DONOR OF PERIPHERAL BLOOD MONONUCLEAR CELLS$41,362
M01 · FY2005 · RR
PHASE I STUDY OF ADOPTIVE IMMUNOTHERAPY AFTER STEM CELL TRANSPLANT$5,706
M01 · FY2005 · RR
SAFETY AND EFFICACY OF CELLULAR ADOPTIVE IMMUNOTHERAPY$5,156
M01 · FY2005 · RR
CD8+T Cell Immunity to Cytomegalovirus$432,500
R01 · FY2004 · AI
Phase I study of adoptive immunotherapy after stem cell transplant$15,614
M01 · FY2004 · RR
CONSENT TO PARTICIPATE AS A DONOR OF PERIPHERAL BLOOD MONONUCLEAR CELLS$4,337
M01 · FY2004 · RR
SAFETY AND EFFICACY OF CELLULAR ADOPTIVE IMMUNOTHERAPY$1,066
M01 · FY2004 · RR
CD8+T Cell Immunity to Cytomegalovirus$432,500
R01 · FY2003 · AI
EVALUATION OF A NOVEL SUICIDE GENE$90,834
P51 · FY2003 · RR
NOVEL SUICIDE GENE FOR THERAPY OF GRAFT VS HOST DISEASE$256,500
U01 · FY2002 · HL
MINOR HISTOCOMPATIBILITY ANTIGEN--GRAFT VERSUS LEUKEMIA$0
P01 · FY2002 · CA
RECONSTITUTION OF CMV IMMUNITY IN HIV-INFECTED HOSTS$919,938
R01 · FY2001 · AI
NOVEL SUICIDE GENE FOR THERAPY OF GRAFT VS HOST DISEASE$256,500
U01 · FY2001 · HL
TREATMENT OF HIV WITH GENE MODIFIED CD8+ T CELL CLONES$0
P01 · FY2001 · AI
TREATMENT OF MALIGNANCY WITH GENE MODIFIED T CELLS AND T CELL CLONES$0
P01 · FY2001 · CA
RECONSTITUTION OF CMV IMMUNITY IN HIV-INFECTED HOSTS$893,465
R01 · FY2000 · AI
TREATMENT OF MALIGNANCY WITH GENE MODIFIED T CELLS AND T CELL CLONES$346,443
P01 · FY2000 · CA
NOVEL SUICIDE GENE FOR THERAPY OF GRAFT VS HOST DISEASE$256,500
U01 · FY2000 · HL
TREATMENT OF HIV WITH GENE MODIFIED CD8+ T CELL CLONES$251,290
P01 · FY2000 · AI